Mode
Text Size
Log in / Sign up
N/A N=56

PMCF Study on the Safety, Performance and Clinical Benefits Data of the Zimmer® Plates and Screws System

Proximal Humeral Fracture · Proximal Tibia Fractures · Diaphyseal Fracture

Enrolled (actual)
56
Serious AEs
12.5%
Results posted
Feb 2025
Primary outcome: Primary: Performance: Fracture Healing — 29; 26; 2; 0 Fractures

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Zimmer Biomet
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Performance: Fracture Healing
29; 26; 2; 0
SECONDARY
Product Safety (Number of Adverse Events, Serious Adverse Events, Adverse Device Effects and Serious Adverse Device Effects)
0; 3; 0; 3; 0; 0
SECONDARY
Tegner Lysholm Knee Score (Proximal Tibia)
87.4
SECONDARY
Oxford Shoulder Score (OSS) (Proximal Humerus)
SECONDARY
EuroQol Five-dimensional Health Questionnaire (EQ-5D-5L) (Diaphysis)
0.70; 80.7

Summary

The study is a monocentric, retro- and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to confirm safety, performance and clinical benefits of the Zimmer® Plates and Screws System (implants and instrumentation) when used to stabilize diaphyseal, proximal humerus and proximal tibia fractures. The primary objective is the assessment of performance by analyzing fracture healing. The secondary objectives are the assessment of safety by recording and analyzing the incidence and frequency of complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified. Subjects' outcomes will also be assessed.

Eligibility Criteria

Inclusion Criteria

Patients having received one of the plates belonging to the Zimmer® Plates and Screws System, designed for temporary internal fixation to stabilize fractures during the normal healing process. In this study we will collect data specifically on Zimmer® Plates and Screws System plates belonging to the Diaphysis, Proximal Humerus and Proximal Tibia groups.

Exclusion Criteria

  • Off-label use
  • Patients under the age of 18
  • Prisoners
  • Severely comminuted fractures in which bone fragments are too small or numerous to adequately fix or maintain a reduced position
  • Infection
  • Metal sensitivity or intolerance
  • Severe osteopenia and/or osteoporosis, or in the presence of marked or rapid bone absorption, metabolic bone disease, cancer, or any other tumor-like condition of the bone which may compromise fixation
  • Sternal or spinal fractures
  • Anatomical location in which the device would interfere with nerves, blood vessels, or other vital structures
  • Patients with inadequate soft tissue coverage at the implant site
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05215613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search